<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168909</url>
  </required_header>
  <id_info>
    <org_study_id>ek.213-07 (IRB)</org_study_id>
    <nct_id>NCT00168909</nct_id>
  </id_info>
  <brief_title>Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)</brief_title>
  <official_title>Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of alfacalcidol 1 µg daily on the number
      of fallers in postmenopausal, alendronate-treated, osteopenic or osteoporotic women.

      primary outcome = number of fallers (patients with at least one locomotor fall incl.mixed
      falls)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary outcome: number of fallers (patients with at least one locomotor fall incl.mixed falls)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary outcome: number of falls (locomotor falls, incl.mixed falls), all falls/fallers, neuromuscular parameters, BMD, biochemical parameters of calcium and bone metabolism; cognition and moods; muscle biopsies</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">282</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <condition>Osteopenia</condition>
  <condition>Falls</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alfacalcidol 1µg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alfacalcidol</intervention_name>
    <description>alfacalcidol 1 µg once daily, oral, for 3 years</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo once daily, oral, for 3 years</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 65 years

          -  postmenopausal women

          -  osteopenia/osteoporosis as defined by WHO criteria

        Exclusion Criteria:

          -  Neoplasm or other severe diseases with life expectancy less than one year or
             expectation of rapid worsening within one year

          -  Chronic inflammatory rheumatoid disease

          -  Arthritis with continuous pain and influence on locomotion

          -  Inflammatory or metabolic bone disease, excluding osteoporosis.

          -  Subjects with antiosteoporotic medications who are not willing to switch over to
             alendronate treatment. Estrogen treatment can be continued

          -  25-OH-Vitamin D3 &lt; 12 ng/ml (12 ng/ml = 30 mmol/L)

          -  Systemic corticosteroid treatments of more than one month within previous 12 months

          -  Intolerability for alfacalcidol

          -  Hypercalcaemia (&gt;2,7 mmol/l)

          -  Milk alkali syndrome

          -  Uncorrected, severe visual impairments

          -  Creatinin &gt; 2.5 mg/dl (&gt;220 µmol/L)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Felsenberg, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Muscle and Bone Research, Aerpah-Kliniken Esslingen</name>
      <address>
        <city>Stuttgart</city>
        <zip>73732</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 8, 2008</last_update_submitted>
  <last_update_submitted_qc>May 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Dieter Felsenberg</name_title>
    <organization>Charité - Campus Benjamin Franklin, Centre for Muscle and Bone Research, Hindenburgdamm 30, 12200 Berlin, Germany</organization>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>frailty</keyword>
  <keyword>falls</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

